peritoneal fluid and serum through TLR9 signaling pathway. When we stimulated B cells with CpG-DNA, production of bacteria-reactive IgM was reproduced in vitro. We established a bacteria-reactive monoclonal IgM antibody using CpG-DNA stimulated-peritoneal B cells. The monoclonal IgM antibody enhanced the phagocytic activity of RAW 264.7 cells against S. aureus MW2 infection. Therefore, we suggest that CpG-DNA enhances the antibacterial activity of the immune system by triggering the production of bacteria-reactive IgM. We also suggest the possible application of the antibodies for the treatment of antibiotics-resistant bacterial infections. [BMB Reports 2019; 52(11): 635-640]
INTRODUCTION
Immunoglobulin M (IgM) exists as two types: natural IgM and immune IgM (1) . Natural antibodies, consisting mostly of the natural IgM, are the antibodies found in the sera of humans and mice without any exposure to antigens (2). In contrast to the natural IgM, immune IgM is the first antibody produced in response to antigenic stimulation (3). Both IgMs have an important role in pathogen defense, especially bacterial infection (4). Several investigators have suggested that the administration of IgM in both in vitro and in vivo models leads to protection against bacterial infection, such as Streptococcus agalactiae (S. agalactiae), Escherichia coli (E. coli), Borrelia hermsii (B. hermsii), Pseudomonas aeruginosa (P. aeruginosa), and Francisella tularensis (F. tularensis) (5-9). Using IgM knock out mice, some reports have also discovered the protective role of IgM expression against bacterial infection, including Streptococcus pneumoniae (S. pneumoniae) and B. hermsii (10, 11).
DNA containing CpG dinucleotide motifs (CpG-DNA), which are found in bacterial DNA, stimulate Toll-like receptor 9 (TLR9) on immune cells, leading to cell proliferation and cytokine production (12). Furthermore, CpG-DNA activates B cells, producing T cell-independent antibodies (13). These roles of CpG-DNA in the immune system are closely related to the prevention of bacterial infection (14-17). Investigators have reported that CpG-DNA activated dendritic cells and the secreted type-1 cytokine, IFN-, have protective roles against bacterial infection in murine models (14, 15) . The antibacterial effects of reactive oxygen species (ROS) produced by the administration of CpG-DNA in osteoblast-like cell lines have also been shown in S. aureus infection (16) . Furthermore, it was reported that CpG-DNA treatment activated macrophages to promote phagocytosis in S. aureus-infected conditions through the JNK/P38 signaling pathway (17) .
Previously, we reported that bacteria-reactive IgG produced by the administration of CpG-DNA enhances the antibacterial effect in murine models (18) ; however, the biological functions of IgM produced by CpG-DNA administration are not known. Here, we confirmed that the production of TLR9-mediated IgM occurred both in the peritoneal cavity and sera of mice and that IgM was produced in the peritoneal B cells in vitro. We isolated a bacteria-reactive monoclonal IgM antibody induced by CpG-DNA administration and found for the first time that the IgM enhances phagocytosis against bacterial infection. http://bmbreports.org After 7 days, the mice were intravenously injected with S. aureus MW2 (1 × 10 7 CFU). Peritoneal fluid and serum were collected from the mice two days after the bacterial infection. Bacteria-reactive IgM in the peritoneal fluid (A) and serum (B) was captured using S. aureus MW2-coated plates (n = 3/group) and the concentrations of IgM were measured by ELISA. 1826, CpG-DNA 1826. MW2, S. aureus MW2. (C-F) BALB/c and (G-J) TLR9 −/− mice were intraperitoneally injected with CpG-DNA 1826. Seven days after the administration of CpG-DNA 1826, the peritoneal fluids (C, E, G, I) and serum (D, F, H, J) were collected. To measure the amounts of IgM reactive to bacteria, the indicated bacteria were added to poly-L-lysine-coated plates, and the amount of bound IgM was determined by ELISA (n = 3/group). The results presented are representative of three independent experiments. *P ＜ 0.05; **P ＜ 0.005; ***P ＜ 0.0005. mice after S. aureus MW2 infection was enhanced by injection of CpG-DNA. Based on our observations, we assumed that bacteria-reactive IgM could be produced by the injection of CpG-DNA 1826 into the peritoneal cavity. To identify the production of IgM by the CpG-DNA treatment in mice, we harvested the peritoneal fluid and serum from the mice after intraperitoneal injection of CpG-DNA 1826 followed by intravenous injection with S. aureus MW2, and measured the levels of IgM reactive to S. aureus MW2 using the ELISA assay. When the mice were intraperitoneally injected with CpG-DNA 1826, the IgM levels were significantly increased both in the peritoneal fluid and serum, especially in the peritoneal fluid. The concentration of the IgM was decreased slightly in the peritoneal fluid and serum following the infection with S. aureus MW2; however, the pretreatment of CpG-DNA 1826 before S. aureus MW2 infection showed a significant increase of the IgM concentration ( Fig. 1A and B ).
To analyze the binding ability of IgM produced by the CpG-DNA administration to various bacterial species, we selected Gram-positive bacterial species (Staphylococcus and Streptococcus) and Gram-negative bacterial species (Klebsiella, Escherichia, Acinetobacter and Pseudomonas) and performed ELISA assays. The results show that the levels of each bacteria-reactive IgM were increased in the peritoneal fluids and serum by intraperitoneal injection of CpG-DNA 1826, and the rate of increase in the peritoneal fluids was significantly higher than that of the serum (Fig. 1C -F).
To determine whether the IgM production induced by the CpG-DNA administration was due to the activation of the TLR9 signaling pathway, we performed the same experiments using BALB/c TLR9 −/− mice. There were no significant changes in IgM production both in the peritoneal fluid and sera of the TLR9 −/− mice even with the injection of CpG-DNA 1826 ( Fig. 1G-J) . Therefore, the results suggest that the TLR9 signaling pathway is involved in the production of bacteria-reactive IgM induced by CpG-DNA stimulation.
Induction of bacterial-reactive IgM in mouse peritoneal cavity cells by CpG-DNA treatment in vitro
To identify where the bacteria-reactive IgM was produced by the CpG-DNA administration, the mice were intraperitoneally injected with CpG-DNA 1826 or non-CpG-DNA 2041, and then the peritoneal fluid, spleen, mesenteric lymph nodes (MLN), and cervical lymph nodes (CLN) were harvested from the mice 7 days after the injection. The cells from the tissues were cultured for 2 days, and the levels of IgM were analyzed in the cell culture supernatants ( Fig. 2A ). The IgM amounts were increased in the culture supernatants of cells prepared from the CpG-DNA 1826-injected peritoneal fluid, but were not increased in the other tissues by CpG-DNA 1826 injection.
To determine whether IgM is produced by CpG-DNA stimulation in vitro, the cells from the tissues were stimulated in vitro with PBS, CpG-DNA 1826 or non-CpG-DNA 2041 for 2 days and the levels of IgM were analyzed in the cell culture http://bmbreports.org BMB Reports ＋ B cells (B2 cells) from the peritoneal cavity lymphocytes (Fig. 2C) . The sorted B cells were treated with CpG-DNA 1826 in vitro for 2 days, and the amounts of IgM in the supernatants of the cell cultures were measured by ELISA (Fig. 2D) . The secreted amounts of IgM in response to CpG-DNA treatment were increased both in the B1 and B2 cells. However, the increase of IgM production by B cells was reduced when the mice were pre-injected with CpG-DNA before the isolation of peritoneal cells, indicating that CpG-DNA influenced the B cell activity in terms of antibody production (Fig. 2D ). The amounts of bacteriareactive IgM in the B cells were increased by CpG-DNA stimulation in vitro; however, the production of the bacteria-reactive IgM by the B2 cells was significantly reduced when CpG-DNA was pre-treated prior to the isolation of the peritoneal cells ( Fig. 2E) . The results suggest that bacteriareactive IgM was produced by the CpG-DNA treatment both in the B1 and B2 cells of the peritoneal cavity; however, there can be some difference in the regulation between the two http://bmbreports.org 
subpopulations.

Production of bacteria-reactive monoclonal IgM antibody
To obtain the bacteria-reactive monoclonal IgM antibody from the mouse peritoneal cavity cells, we screened the hybridoma cells secreting CpG-DNA-induced IgM. Seven days after the intraperitoneal injection of CpG-DNA 1826, the peritoneal cavity cells were harvested from the mice, and they were fused with myeloma SP2/0 cells, and screened in selective medium. After screening a hybridoma clone (3F3F5) secreting the bacteria-reactive monoclonal IgM antibody, the cells were cultured serum-free medium for 5 days. The bacteria-reactive monoclonal IgM antibody was purified from the culture supernatants using ion-exchange chromatography, followed by gel filtration chromatography. The IgM protein fractions were collected, loaded and run on a SDS-PAGE, and stained with Coomassie brilliant blue R solution (Fig. 3A) . The fractions including the purified IgM were analyzed by Western blotting (Fig. 3B) . We confirmed the ability of the purified monoclonal IgM antibody to bind several Gram-positive bacteria by ELISA ( Fig. 3C ).
Bacteria-reactive monoclonal IgM antibody enhances phagocytosis of S. aureus MW2 in RAW 264.7 cells
To perform the phagocytosis assay in vitro, we selected murine macrophage cell line RAW 264.7. To investigate the phagocytosis efficacy of the bacteria-reactive monoclonal IgM antibody, we incubated fluorescein isothiocyanate (FITC)-labeled S. aureus MW2 with PBS, normal mouse IgM, or bacteriareactive monoclonal IgM antibody (3F3F5 IgM). The RAW 264.7 cells were treated with the antibody-bound S. aureus MW2, and then, phagocytosis was observed by confocal microscopy (Fig. 4A, B) . The results indicate that the efficacy of phagocytosis was increased in the presence of the bacteria-reactive monoclonal IgM antibody or normal mouse IgM. However, there was no difference in phagocytic efficacy between the two IgM suggesting that the amounts of bacteria-reactive IgM were increased in the peritoneal cavity and sera following the injection of CpG-DNA 1826 (Fig. 1) but the phagocytic ability of the bacteria-reactive antibody was not enhanced by the administration of CpG-DNA 1826 compared to normal mouse IgM.
DISCUSSION
S. aureus has been recognized as a major cause of many infectious diseases including life-threatening diseases such as pneumoniae, sepsis, and endocarditis (19) . Excessive use of multiple antibiotics to treat S. aureus infection has led to the emergence of methicillin-resistant staphylococcus aureus (MRSA) (20) . As the efficacy of antibiotics decreases and the emergence of MRSA increases, a new strategy to replace antibiotics is urgently required. Several reports have suggested the development of vaccination and passive immunization using protective antibodies as an alternative strategy against MRSA infections (21) (22) (23) .
In our previous experiments, we confirmed that CpG-DNA treatment enhanced the host protection following S. aureus infection, producing bacteria-reactive IgG antibodies which also have a protective role against infection (18) . Here, we hypothesized that the CpG-DNA-induced production of antibodies, especially IgM, would be involved in the anti-bacterial effect of CpG-DNA. Because the levels of the bacteria-reactive IgM antibodies were significantly increased both in the peritoneal cavity and serum of mice following the administration of CpG-DNA ( Fig. 1) , we predicted that CpG-DNA triggered the activation of some B cell populations, producing bacteria-reactive IgM.
Natural antibodies, which exist without any exposure to antigens, have a broad antibacterial activity, and prevent several bacterial infections (24) . Here, we confirmed that the amount of IgM produced by the CpG-DNA treatment was greatly increased in the peritoneal cavity of the mice and had a broad reactivity against several bacteria (Fig. 1) . We suppose that the bacteria-reactive IgM has broad reactivity because the epitopes of the antibody might be common bacterial surface components such as carbohydrate, glycoprotein, and/or metabolites.
In addition, the secretion of IgM antibodies by the CpG-DNA treatment was significantly increased in the peritoneal cells when we isolated the peritoneal cells, spleen, MLN, and CLN and stimulated them with CpG-DNA in vitro (Fig. 2) . It has been reported that most of the B1 cells were in the peritoneal cavity and produced broad bacterial-reactive antibodies against microbial agents (25, 26) . We found that the bacteria-reactive IgM was produced both in the peritoneal B1 and B2 cells, but higher levels of IgM were produced in the B1 cells than in the B2 cells (Fig. 2) . Researchers have shown the efficacy of antibody-mediated phagocytosis against bacterial infection as a measure of the anti-bacterial effect in phagocytic cells (24, 27) . When we examined the effects of the bacteria-reactive monoclonal IgM antibody (3F3F5 mIgM) against bacterial infection, the efficacy of phagocytosis against S. aureus MW2 infection in RAW 264.7 cells was enhanced by the monoclonal IgM antibody which was comparable to normal IgM (Fig. 4) . Based on the results, we consider that 3F3F5 mIgM could be a potent therapeutic agent against bacterial infection in emergency.
In conclusion, we proved that the bacteria-reactive IgM produced by CpG-DNA has protective roles against S. aureus infection by enhanced antibody-mediated phagocytosis in murine macrophage cell line. Despite numerous studies on the development of therapeutic antibodies against bacterial infection, no clinical antibodies have yet been approved. Therefore, future studies on infection therapy should include the development of a humanized antibody against MRSA infection, and this development might be useful to treat infectious diseases.
MATERIALS AND METHODS
CpG-DNA administration
CpG-DNA 1826 and non-CpG-DNA 2041, whose backbones of the sequences were modified with phosphorothioate, were synthesized by GenoTech Co. The following sequences were used: CpG-DNA 1826, 5'-TCCATGACGTTCCTGACGTT-3' and non-CpG-DNA 2041 as a negative control, 5'-CTGGTCTTTCTGGTTTTTTTCTGG-3'. The oligodeoxynucleotides were dissolved in distilled water, injected intraperitoneally in BALB/c mice or TLR9 −/− mice (50 g/ mouse).
In vitro stimulation of mouse primary cells with CpG-DNA
Primary cells were harvested from the mice, homogenized, and re-suspended in RPMI 1640 medium containing 5% FBS. After removing the erythrocytes, the cells were cultured in RPMI 1640 medium containing 5% FBS with 100 U/ml of penicillin and 100 g/ml of streptomycin. Next, each cell culture plate was treated with PBS or 5 g/ml of CpG-DNA 1826 or 5 g/ml of non-CpG-DNA 2041. After 48 h, the cell culture supernatants were harvested and analyzed by ELISA to quantify the IgM levels.
Sorting B cells from mouse peritoneal cells
Peritoneal cells were stained with antibodies in sorting buffer (1 mM EDTA, 25 mM HEPES pH 7.0, 1% FBS diluted in PBS).
To isolate the B cells, the peritoneal cells were incubated with anti-mouse CD19 (BD Biosciences, San Jose, CA, USA) and anti-mouse CD23 (eBioscience, San Diego, CA, USA). To sort non-B cells from the peritoneal cells, anti-mouse CD3 (BD Bioscience) was used to isolate T cells. B1 cells and B2 cells were sorted using a FACSAria TM II system (Becton Dickinson Inc.).
Purification of monoclonal IgM antibody
IgM-secreting hybridoma cells (3F3F5 clone) were applied to the Hybridoma-SFM (Thermo Fisher Scientific Inc.), and grown at 125 rpm in a shaker incubator containing 8% CO2 at 37 o C. After 5 days, cell culture supernatants were obtained by centrifugation at 3,000 rpm for 10 min, and purified using DEAE Sepharose TM Fast Flow (GE Healthcare Co.) and HiPrep TM 
